Dyne Therapeutics, Inc.
A clinical-stage biotechnology company developing medicines for inherited muscle diseases such as Duchenne muscular dystrophy and myotonic dystrophy. Its FORCE platform delivers RNA-based therapies directly to muscle tissue. Founded in 2017 and incubated by venture firm Atlas Venture, the company takes its name from the "dyne," a unit of force in physics — a fitting nod to its mission of restoring muscle strength.
| Holder | Schedule | % of class | Shares | Filed |
|---|---|---|---|---|
| JANUS HENDERSON GROUP Ltd. | 13G/APassive | 7.3% | 12.00M | Aug 13, 2026 |
| Atlas Venture Fund XI, L.P. | 13G/APassive | 2.4% | 4.48M | Aug 13, 2026 |
| Atlas Venture Associates XI, L.P. | 13G/APassive | 2.4% | 4.48M | Aug 13, 2026 |
| Atlas Venture Associates XI, LLC | 13G/APassive | 2.4% | 4.48M | Aug 13, 2026 |
| Atlas Venture Opportunity Fund II, L.P. | 13G/APassive | 0.7% | 1.34M | Aug 13, 2026 |
| Atlas Venture Associates Opportunity II, L.P. | 13G/APassive | 0.7% | 1.34M | Aug 13, 2026 |
| Atlas Venture Associates Opportunity II, LLC | 13G/APassive | 0.7% | 1.34M | Aug 13, 2026 |
| Atlas Venture Opportunity Fund I, L.P. | 13G/APassive | 0.5% | 975.9K | Aug 13, 2026 |
| Atlas Venture Associates Opportunity I, L.P. | 13G/APassive | 0.5% | 975.9K | Aug 13, 2026 |
| Atlas Venture Associates Opportunity I, LLC | 13G/APassive | 0.5% | 975.9K | Aug 13, 2026 |